UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017958
Receipt number R000020813
Scientific Title Developing a diagnostic method for pancreatic cancer at the very early stage
Date of disclosure of the study information 2015/06/18
Last modified on 2023/12/06 17:24:44

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Developing a diagnostic method for pancreatic cancer at the very early stage

Acronym

Developping a diagnostic method for pancreatic cancer at the very early stage

Scientific Title

Developing a diagnostic method for pancreatic cancer at the very early stage

Scientific Title:Acronym

Developping a diagnostic method for pancreatic cancer at the very early stage

Region

Japan


Condition

Condition

Intraductal papillary mucinous neoplasm (IPMN), Pancreatic cancer

Classification by specialty

Hepato-biliary-pancreatic medicine Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

Developing the diagnostic method for pancreatic cancer at the very early stage

Basic objectives2

Bio-equivalence

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Better diagnostic performance is obtained than existing tumor markers

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The consent for registration is obtained

Key exclusion criteria

The consent for registration is not understood

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Atsushi
Middle name
Last name Hagihara

Organization

Osaka City University

Division name

Department of Hepatology

Zip code

545-8585

Address

1-4-3, Asahi-machi, Abeno-ku, Osaka

TEL

06-6645-3811

Email

hagy@med.osaka-cu.ac.jp


Public contact

Name of contact person

1st name Atsushi
Middle name
Last name Hagihara

Organization

Osaka City University

Division name

Department of Hepatology

Zip code

545-8585

Address

1-4-3, Asahi-machi, Abeno-ku, Osaka

TEL

06-6645-3811

Homepage URL


Email

hagy@med.osaka-cu.ac.jp


Sponsor or person

Institute

Osaka City University

Institute

Department

Personal name



Funding Source

Organization

MHLW/AMED

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics, Osaka City University

Address

1-2-7, Asahi-machi, Abeno-ku, Osaka

Tel

06-6645-3434

Email

ethics@med.osaka-cu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

大阪市立大学(大阪府)、京都大学(京都府)、国立がん研究センター(東京都)


Other administrative information

Date of disclosure of the study information

2015 Year 06 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 05 Month 26 Day

Date of IRB

2014 Year 06 Month 30 Day

Anticipated trial start date

2014 Year 05 Month 26 Day

Last follow-up date

2020 Year 03 Month 31 Day

Date of closure to data entry

2020 Year 03 Month 31 Day

Date trial data considered complete

2020 Year 03 Month 31 Day

Date analysis concluded



Other

Other related information

Developing the diagnotic method for pancreatic cancer at very early stage, utilizing the relation between expression of micro RNA and status of DNA methylation


Management information

Registered date

2015 Year 06 Month 18 Day

Last modified on

2023 Year 12 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020813


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name